[HTML][HTML] Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

SL Baldwin, VA Reese, SE Larsen, E Beebe… - Plos one, 2021 - journals.plos.org
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

[PDF][PDF] Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

SL Baldwin, VA Reese, SE Larsen, E Beebe… - PLoS ONE, 2021 - scholar.archive.org
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

[HTML][HTML] Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

SL Baldwin, VA Reese, SE Larsen, E Beebe… - PLoS ONE, 2021 - ncbi.nlm.nih.gov
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

SL Baldwin, VA Reese, SE Larsen, E Beebe… - PloS …, 2021 - pubmed.ncbi.nlm.nih.gov
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.

SL Baldwin, VA Reese, SE Larsen, E Beebe… - PLoS …, 2021 - search.ebscohost.com
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.

SL Baldwin, VA Reese, SE Larsen, E Beebe… - Plos one, 2021 - europepmc.org
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

[引用][C] Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

SL Baldwin, VA Reese, SE Larsen, E Beebe… - PLoS …, 2021 - ui.adsabs.harvard.edu
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant
formulations in the mouse model - NASA/ADS Now on home page ads icon ads Enable full …

[PDF][PDF] Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

SL Baldwin, VA Reese, SE Larsen, E Beebe… - PLoS …, 2021 - pdfs.semanticscholar.org
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.

SL Baldwin, VA Reese, SE Larsen, E Beebe… - PLoS ONE, 2021 - go.gale.com
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …